Global microRNA expression and survival in patients with metastatic colorectal cancer in third-line treatment with cetuximab and irinotecan

被引：0
|
作者：
Schou, J. V.
Johansen, J. S.
Jensen, B. V.
Nielsen, D. L.
Kruhoffer, M.
机构：
[1] Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[2] Univ Copenhagen, Herlev Hosp, Dept Oncol, Copenhagen, Denmark
[3] Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[4] Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[5] Aarhus Hosp, Dept Clin Chem, Aarhus, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3602
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Prediction of survival in patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan through changes in microRNA expression in whole blood during treatment
    Schou, J. V.
    Andersen, K. K.
    Jensen, B. V.
    Nielsen, D. L.
    Pfeiffer, P.
    Hogdall, E. V.
    Yilmaz, M.
    Kruhoffer, M.
    Johansen, J. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Irinotecan combined with Panitumumab or cetuximab as third-line treatment for metastatic colorectal cancer.
    Braghiroli, Maria Ignez
    Batistuzzo Vicentini, Maria Fernanda
    da Fonseca, Leonardo Gomes
    Souza, Karla Teixeira
    Bonadio, Renata Colombo
    Melro Braghiroli, Oddone Freitas
    Machado Mathias, Maria Cecilia
    Talans, Aley
    Zambrano Mendoza, Maria Elizabeth
    Martins, Juliana Goes
    Sabagga, Jorge
    Motta Venchiarutti Moniz, Camila Venchiarutti
    Hoff, Paulo Marcelo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15551 - E15551
  • [3] TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer
    Spindler, Karen-Lise Garm
    Christensen, Ib Jarle
    Nielsen, Hans Jorgen
    Jakobsen, Anders
    Bruenner, Nils
    [J]. TUMOR BIOLOGY, 2015, 36 (06) : 4301 - 4308
  • [4] Impact of microRNA miR-345 in blood on survival and response in 144 patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan.
    Schou, Jakob Vasehus
    Andersen, Klaus Kaae
    Jensen, Benny Vittrup
    Nielsen, Dorte Lisbet
    Hogdall, Estrid V.
    Johansen, Julia S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [5] Is cetuximab in combination with irinotecan as a third-line treatment for advanced colorectal cancer scientifically justified?
    Krakowska, Magdalena
    Czyzykowski, Rafal
    Potemski, Piotr
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2016, 12 (06): : 205 - 208
  • [6] Impact of third-line treatment with irinotecan plus cetuximab on non-tumor standardized uptake values in patients with metastatic colorectal cancer
    Andersen, Kim Francis
    Skougaard, Kristin
    Nielsen, Anne Lerberg
    Hendel, Helle Westergren
    [J]. ONCOLOGY LETTERS, 2012, 4 (01) : 131 - 134
  • [7] Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
    Moe, M.
    Micallef, R. A.
    Pwint, T.
    Maughan, T.
    Mort, D.
    Wagstaff, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer
    Romeo, M.
    Soler, G.
    Martinez Villacampa, M.
    Laquente, B.
    Lopez Doriga, A.
    Pisa, A.
    Rey, M.
    Santos, C.
    Salazar, R.
    Germa Lluch, J. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Cetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience
    Pantelic, Aleksandra
    Markovic, Milan
    Pavlovic, Milan
    Jancic, Snezana
    [J]. JOURNAL OF BUON, 2016, 21 (01): : 70 - 79
  • [10] Metastatic Colorectal Cancer: Strategies for Third-Line Treatment
    Marshall, John L.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 7 - 15
12345